Stenocare (CPH:STENO) Third Quarter 2022 Results
Key Financial Results- Net loss: kr.4.35m (loss widened by 56% from 3Q 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Stenocare's share price is broadly unchanged from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 4 warning signs for Stenocare (3 are significant!) that you need to be mindful of.New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About CPSE:STENO
Stenocare
Stenocare A/S cultivates, produces, imports, sells, and distributes prescription-based medical cannabis products to patients in the Danish and European markets.
Flawless balance sheet slight.
